Poor Outcomes in Infants with Metastatic Neuroblastoma
Author Information
Author(s): Minard V, Hartmann O, Peyroulet M C, Michon J, Coze C, Defachelle A S, Lejars O, Perel Y, Bergeron C, Boutard P, Leverger G, Stephan J L, Thyss A, Chastagner P, Couillault G, Devalck C, Lutz P, Mechinaud F, Millot F, Plantaz D, Rialland X, Rubie H
Primary Institution: Institut Gustave Roussy
Hypothesis
Does MYCN amplification and the presence of bone lesions affect the prognosis of infants with stage 4 neuroblastoma?
Conclusion
Infants with stage 4 neuroblastoma and bone lesions have a significantly poorer prognosis, especially when MYCN is amplified.
Supporting Evidence
- MYCN oncogene was amplified in 37% of the tumors.
- The 5-year event-free survival rate was 64.1%.
- Bone lesions were the most powerful unfavourable prognostic indicator.
Takeaway
This study found that babies with a serious type of cancer called neuroblastoma do worse if they have certain problems like bone lesions.
Methodology
The study enrolled 51 infants with stage 4 neuroblastoma and analyzed their outcomes based on the presence of bone lesions and MYCN amplification.
Limitations
The study may not account for all variables affecting prognosis and was limited to a specific patient population.
Participant Demographics
Infants aged less than 1 year with stage 4 neuroblastoma.
Statistical Information
P-Value
< 0.0001
Confidence Interval
± 7.1%
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website